In the increasingly crowded PD-(L)1 inhibitors market,
KEYTRUDA maintains a dominant position, holding more than 50%
market share in 2023 it is deeply entrenched with approval across
20 indications. Among the 10 approved drugs, early entrants OPDIVO
and KEYTRUDA continue to command a major share of the
market.
LAS
VEGAS, July 2, 2024 /PRNewswire/ --
DelveInsight's PD-(L)1 Inhibitors Market Insights report
includes a comprehensive understanding of current treatment
practices, emerging PD-(L)1 inhibitors, market share of individual
therapies, and current and forecasted market size from 2020 to
2034, segmented into 7MM [the United
States, the EU4 (Germany,
France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the PD-(L)1 Inhibitors Market
Report
- According to DelveInsight's analysis, the market size of
PD-(L)1 inhibitors in the 7MM was nearly USD 36 billion in 2023, and the largest
market size was generated by the United
States.
- In the competitive landscape of PD-1 inhibitors,
KEYTRUDA dominates the US market, while OPDIVO leads
in Japan.
- LIBTAYO is the market leader for non-melanoma skin
cancers, such as cutaneous squamous cell carcinoma and basal cell
carcinoma, and is expected to maintain its dominance in the coming
years. TECENTRIQ holds the leading position in small-cell
lung cancer.
- NSCLC is the leading indication for PD-(L)1 inhibitors in the
7MM with total incident cases of nearly ∼200,000 in
2023, which is expected to increase by 2034 in the US.
- Leading PD-(L)1 inhibitor companies such as EQRx,
CStone Pharmaceuticals, Pfizer, Novartis, Arcus Biosciences,
Agenus, Tracon Pharmaceuticals, Shanghai Henlius Biotech, Incyte
Corporation, and others are developing novel PD-(L)1 inhibitors
that can be available in the PD-(L)1 inhibitors market in the
coming years.
- The promising PD-(L)1 inhibitors in the pipeline include
sugemalimab, sasanlimab, spartalizumab, zimberelimab,
balstilimab, envafolimab, HLX10, INCB099280, and others.
- In April 2024, Bristol Myers
Squibb announced that the Committee for Medicinal Products for
Human Use (CHMP) recommended approval of OPDIVO in combination with
cisplatin and gemcitabine for the first-line treatment of adult
patients with unresectable or metastatic urothelial carcinoma. The
European Commission will review the CHMP recommendation. The final
EC decision is expected in June
2024.
- In March 2024, Chugai
Pharmaceutical filed a regulatory application with the Ministry
of Health, Labour and Welfare (MHLW) for TECENTRIQ IV infusion
1,200 mg for an additional indication of alveolar soft part
sarcoma.
Discover which therapies are expected to grab the major PD-(L)1
inhibitors market share @ PD-(L)1 Inhibitors Market
Report
PD-(L)1 Inhibitors Overview
PD-(L)1 inhibitors are a class of immunotherapy drugs that have
transformed the treatment landscape for various cancers. The "PD"
stands for programmed death, and "L1" refers to its ligand, PD-L1.
These inhibitors work by blocking the interaction between PD-1, a
checkpoint protein on T cells, and PD-L1, a protein expressed in
cancer cells and some immune cells. Under normal conditions, this
interaction helps maintain immune homeostasis and prevent
autoimmunity. However, many cancers exploit this pathway to evade
immune detection by upregulating PD-L1, thereby "turning off" T
cells and preventing them from attacking the tumor. By inhibiting
this interaction, PD-(L)1 inhibitors reinvigorate T cells, allowing
them to recognize and destroy cancer cells more effectively.
The advent of PD-(L)1 inhibitors has significantly improved the
prognosis for patients with several types of cancers, including
melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma,
and Hodgkin lymphoma. These inhibitors, such as KEYTRUDA
(pembrolizumab) and OPDIVO (nivolumab), have shown
remarkable efficacy in clinical trials, leading to durable
responses and prolonged survival in many patients who previously
had limited treatment options. Despite their success, PD-(L)1
inhibitors are not universally effective, and some patients
experience immune-related adverse events due to heightened immune
activation. Ongoing research aims to refine these therapies,
identify biomarkers for better patient selection, and combine them
with other treatments to enhance their efficacy and manage their
side effects more effectively.
PD-(L)1 Inhibitors Market Overview
In recent years, cancer immunotherapy has seen significant
progress, with several treatments receiving FDA approval. The
PD-(L)1 pathway, which allows tumors to evade the immune system,
has emerged as a promising target for therapy. The creation of
anti-PD-1 and anti-PD-L1 drugs has ushered in a new era of cancer
treatment. Clinical trials have demonstrated promising results
across various tumor types, and the medical community eagerly
anticipates further findings from ongoing and completed
studies.
PD-1 inhibitors are poised to become the top-selling drug class
in the future. Immuno-oncology drugs, particularly those targeting
PD-(L)1, have revolutionized cancer therapy across various tumor
types and stages, from advanced to early stages. The widespread
adoption of PD-(L)1 therapies is driven by their proven
adaptability. They can be used alone or alongside targeted
treatments like tyrosine kinase inhibitors, chemotherapy, or other
immunotherapies. This adaptability has resulted in long-lasting
tumor responses and enhanced survival rates, all while maintaining
manageable side effects. The better safety profile of PD-(L)1
therapies compared to chemotherapy allows them to serve as a
foundational treatment in many combination therapies.
Merck's KEYTRUDA led the way as the first PD-1
inhibitor approved in the United
States in September 2014,
initially for advanced melanoma. Currently, KEYTRUDA's
expansion is fueled by growing global usage in earlier-stage
cancers such as triple-negative breast cancer and renal
cell carcinoma, along with NSCLC in the US, and
sustained high demand for advanced cancers worldwide. Both
OPDIVO + YERVOY and KEYTRUDA plus axitinib are now widely
recognized as primary treatments for advanced renal cell carcinoma.
OPDIVO has gained approval in combination with cisplatin and
gemcitabine chemotherapies as a first-line treatment for
unresectable or advanced urothelial carcinoma.
Learn more about the FDA-approved PD-(L)1 inhibitors @
PD-(L)1 Inhibitors
Pipeline PD-(L)1 Inhibitors and Key Companies
- Sugemalimab: EQRx/CStone Pharmaceuticals
- Sasanlimab: Pfizer
- Spartalizumab: Novartis
- Zimberelimab: Arcus Biosciences
- Balstilimab: Agenus
- Envafolimab: Tracon Pharmaceuticals
- HLX10: Shanghai Henlius Biotech
- INCB099280: Incyte Corporation
Discover more about PD-(L)1 inhibitor drugs in development
@ PD-(L)1 Inhibitors Clinical Trials
PD-(L)1 Inhibitors Market Dynamics
The dynamics of the PD-(L)1 inhibitors market are expected to
change in the coming years. PD-(L)1 inhibitors have demonstrated
impressive efficacy across various lines of therapy,
providing valuable options for patients at different stages of
their cancer journey, with some achieving durable responses and
prolonged survival outcomes. The approval of the IMFINZI +
IMJUDO combination after 11 and a half years in the US,
alongside other options like OPDIVO + YERVOY, expands
treatment choices for NSCLC, liver cancer, and BTC.
There's potential for drugs synergizing with checkpoint
inhibitors, offering a large market opportunity for
next-generation immunotherapies. While certain inhibitors like
KEYTRUDA dominate NSCLC, OPDIVO in melanoma and renal
cancer, and TECENTRIQ in SCLC, emerging PD-(L)1 inhibitors
could capture significant market shares in other indications.
However, several factors may hinder the growth of the PD-(L)1
inhibitor market. Geographical disparities in biomarker
testing recommendations hinder consistent patient care and
treatment decision-making, despite broad agreement on the
importance of biomarker testing for patients with cancer, leading
to variable uptake in clinical practice. The PD-(L)1 market
faces challenges due to the growing complexity and
competition from the increasing number of approved therapies
and combinations, making it more difficult to navigate
effectively.
Next-generation immunotherapies, like the TIGIT class,
aimed to replicate the success of anti-PD-1 drugs in the NSCLC
market but failed to show a significant impact, leaving
conservative projections for TIGIT's potential in NSCLC. The
expected entry of PD-1/PD-L1 biosimilars may erode market
sales, and the pursuit of combination products could impact patient
access to therapies.
PD-(L)1 Inhibitors
Market Report Metrics
|
Details
|
Study Period
|
2020–2034
|
Coverage
|
7MM [the United States,
the EU4 (Germany, France, Italy, and Spain) and the United Kingdom,
and Japan].
|
PD-(L)1 Inhibitors
Market CAGR
|
5 %
|
PD-(L)1 Inhibitors
Market Size in 2023
|
USD 36
billion
|
Key PD-(L)1 Inhibitors
Companies
|
EQRX, CStone
Pharmaceuticals, Pfizer, Novartis, Arcus Biosciences, Agenus,
Tracon Pharmaceuticals, Shanghai Henlius Biotech, Incyte
Corporation, and others
|
Key Pipeline PD-(L)1 Inhibitors
|
Sugemalimab,
Sasanlimab, Spartalizumab, Zimberelimab, Balstilimab, Envafolimab,
HLX10, INCB099280, and
others
|
Scope of the PD-(L)1 Inhibitors Market
Report
- Therapeutic Assessment: PD-(L)1 Inhibitors current
marketed and emerging therapies
- PD-(L)1 Inhibitors Market Dynamics: Key
Market Forecast Assumptions of Emerging PD-(L)1
Inhibitors Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis
and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, PD-(L)1
Inhibitors Market Access and Reimbursement
To know more about PD-(L)1 inhibitors treatment guidelines,
visit @ PD-(L)1 Inhibitors Management
Table of Contents
1
|
KEY INSIGHTS
|
2
|
REPORT
INTRODUCTION
|
3
|
EXECUTIVE SUMMARY OF
PD-(L)1 INHIBITORS
|
4
|
KEY EVENTS
|
5
|
EPIDEMIOLOGY AND MARKET
FORECAST METHODOLOGY
|
6
|
PD-(L)1 INHIBITORS
MARKET OVERVIEW AT A GLANCE IN THE 7MM
|
6.1
|
MARKET SHARE (%)
DISTRIBUTION BY INDICATIONS IN 2020
|
6.2
|
MARKET SHARE (%)
DISTRIBUTION BY INDICATIONS IN 2034
|
7
|
PD-(L)1 INHIBITORS
BACKGROUND AND OVERVIEW
|
7.1
|
INTRODUCTION
|
7.2
|
TYPES OF CHECKPOINT
INHIBITORS
|
7.3
|
POTENTIAL OF PD1/PD-L1
INHIBITORS IN THE TREATMENT OF DIFFERENT CANCER
|
7.4
|
PREDICTIVE
BIOMARKERS
|
7.5
|
CLINICAL APPLICATIONS
OF PD-(L)1 INHIBITORS
|
8
|
EPIDEMIOLOGY AND
PATIENT POPULATION
|
8.1
|
ASSUMPTIONS AND
RATIONALE: 7MM
|
8.2
|
TOTAL INCIDENT CASES OF
SELECTED INDICATIONS FOR PD-(L)1 INHIBITORS IN THE 7MM
|
9
|
MARKETED
DRUGS
|
9.1
|
KEY CROSS
COMPETITION
|
9.2
|
TEVIMBRA
(tislelizumab-jsgr): BEIGENE
|
9.2.1
|
Product
Description
|
9.2.2
|
Regulatory
Milestone
|
9.2.3
|
Pivotal Clinical
Trial
|
9.2.4
|
Other Developmental
Activities
|
9.2.5
|
Clinical
Development
|
9.2.5.1
|
Clinical Trials
Information
|
9.2.6
|
Safety and
Efficacy
|
9.3
|
LOQTORZI (toripalimab):
COHERUS BIOSCIENCES/SHANGHAI JUNSHI BIOSCIENCES
|
9.3.1
|
Product
Description
|
9.3.2
|
Regulatory
Milestone
|
9.3.3
|
Pivotal Clinical
Trial
|
9.3.4
|
Other Developmental
Activities
|
9.3.5
|
Clinical
Development
|
9.3.5.1
|
Clinical Trials
Information
|
9.3.6
|
Safety and
Efficacy
|
9.4
|
ZYNYZ
(retifanlimab-dlwr): INCYTE
|
9.4.1
|
Product
Description
|
9.4.2
|
Regulatory
Milestones
|
9.4.3
|
Pivotal Clinical
Trial
|
9.4.4
|
Other Developmental
Activities
|
9.4.5
|
Clinical
Development
|
9.4.5.1
|
Clinical Trial
Information
|
9.4.6
|
Safety and
Efficacy
|
9.5
|
JEMPERLI (dostarlimab):
GLAXOSMITHKLINE (GSK)
|
9.5.1
|
Product
Description
|
9.5.2
|
Regulatory
Milestone
|
9.5.3
|
Pivotal Clinical
Trial
|
9.5.4
|
Other Developmental
Activities
|
9.5.5
|
Clinical
Development
|
9.5.5.1
|
Clinical Trials
Information
|
9.5.6
|
Safety and
Efficacy
|
9.6
|
LIBTAYO
(cemiplimab-rwlc): REGENERON/SANOFI
|
9.6.1
|
Product
Description
|
9.6.2
|
Regulatory
Milestones
|
9.6.3
|
Pivotal Clinical
Trial
|
9.6.4
|
Other Developmental
Activities
|
9.6.5
|
Clinical
Development
|
9.6.5.1
|
Clinical Trial
Information
|
9.6.6
|
Safety and
Efficacy
|
9.7
|
IMFINZI (durvalumab):
ASTRAZENECA
|
9.7.1
|
Product
Description
|
9.7.2
|
Regulatory
Milestones
|
9.7.3
|
Pivotal Clinical
Trial
|
9.7.4
|
Other Developmental
Activities
|
9.7.5
|
Clinical
Development
|
9.7.5.1
|
Clinical Trial
Information
|
9.7.6
|
Safety and
Efficacy
|
9.8
|
BAVENCIO (avelumab):
MERCK
|
9.8.1
|
Product
Description
|
9.8.2
|
Regulatory
Milestone
|
9.8.3
|
Pivotal Clinical
Trial
|
9.8.4
|
Other Developmental
Activities
|
9.8.5
|
Clinical
Development
|
9.8.5.1
|
Clinical Trials
Information
|
9.8.6
|
Safety and
Efficacy
|
9.9
|
TECENTRIQ
(atezolizumab): GENENTECH/HOFFMANN-LA ROCHE
|
9.9.1
|
Product
Description
|
9.9.2
|
Regulatory
Milestone
|
9.9.3
|
Pivotal Clinical
Trial
|
9.9.4
|
Other Developmental
Activities
|
9.9.5
|
Clinical
Development
|
9.9.5.1
|
Clinical Trials
Information
|
9.9.6
|
Safety and
Efficacy
|
9.1
|
OPDIVO (nivolumab):
BRISTOL-MYERS SQUIBB AND ONO PHARMACEUTICAL
|
9.10.1
|
Product
Description
|
9.10.2
|
Regulatory
Milestone
|
9.10.3
|
Pivotal Clinical
Trial
|
9.10.4
|
Other Developmental
Activities
|
9.10.5
|
Clinical
Development
|
9.10.5.1
|
Clinical Trials
Information
|
9.10.6
|
Safety and
Efficacy
|
9.11
|
KEYTRUDA
(pembrolizumab): MERCK
|
9.11.1
|
Product
Description
|
9.11.2
|
Regulatory
Milestone
|
9.11.3
|
Pivotal Clinical
Trial
|
9.11.4
|
Other Developmental
Activities
|
9.11.5
|
Clinical
Development
|
9.11.5.1
|
Clinical Trial
Information
|
9.11.6
|
Safety and
Efficacy
|
10
|
EMERGING
DRUGS
|
10.1
|
KEY CROSS
COMPETITION
|
10.2
|
SUGEMALIMAB (CS1001):
EQRX/CSTONE PHARMACEUTICALS
|
10.2.1
|
Product
Description
|
10.2.2
|
Other Developmental
Activities
|
10.2.3
|
Clinical
Development
|
10.2.3.1
|
Clinical Trials
Information
|
10.2.4
|
Safety and
Efficacy
|
10.3
|
SASANLIMAB:
PFIZER
|
10.3.1
|
Product
Description
|
10.3.2
|
Other Developmental
Activities
|
10.3.3
|
Clinical
Development
|
10.3.3.1
|
Clinical Trials
Information
|
10.3.4
|
Safety and
Efficacy
|
10.4
|
SPARTALIZUMAB:
NOVARTIS
|
10.4.1
|
Product
Description
|
10.4.2
|
Clinical
Development
|
10.4.2.1
|
Clinical Trials
Information
|
10.4.3
|
Safety and
Efficacy
|
10.5
|
ZIMBERELIMAB: ARCUS
BIOSCIENCES
|
10.5.1
|
Product
Description
|
10.5.2
|
Other Developmental
Activities
|
10.5.3
|
Clinical
Development
|
10.5.3.1
|
Clinical Trials
Information
|
10.5.4
|
Safety and
Efficacy
|
10.6
|
BALSTILIMAB:
AGENUS
|
10.6.1
|
Product
Description
|
10.6.2
|
Other Developmental
Activities
|
10.6.3
|
Clinical
Development
|
10.6.3.1
|
Clinical Trial
Information
|
10.6.4
|
Safety and
Efficacy
|
10.7
|
ENVAFOLIMAB: TRACON
PHARMACEUTICALS
|
10.7.1
|
Product
Description
|
10.7.2
|
Other Developmental
Activities
|
10.7.3
|
Clinical
Development
|
10.7.3.1
|
Clinical Trial
Information
|
10.7.4
|
Safety and
Efficacy
|
10.8
|
HLX10: SHANGHAI HENLIUS
BIOTECH
|
10.8.1
|
Product
Description
|
10.8.2
|
Other Developmental
Activities
|
10.8.3
|
Clinical
Development
|
10.8.3.1
|
Clinical Trial
Information
|
10.8.4
|
Safety and
Efficacy
|
10.9
|
INCB099280: INCYTE
CORPORATION
|
10.9.1
|
Product
Description
|
10.9.2
|
Other Developmental
Activities
|
10.9.3
|
Clinical
Development
|
10.9.3.1
|
Clinical Trials
Information
|
10.9.4
|
Safety and
Efficacy
|
11
|
PD-(L)1 INHIBITORS: THE
7MM ANALYSIS
|
11.1
|
KEY FINDINGS
|
11.2
|
MARKET
OUTLOOK
|
11.3
|
KEY MARKET FORECAST
ASSUMPTIONS
|
11.3.1
|
Cost Assumptions and
Rebates
|
11.3.2
|
Pricing
Trends
|
11.3.3
|
Analogue
Assessment
|
11.3.4
|
Launch Years and
Therapy Uptake
|
11.4
|
TOTAL MARKET SIZE OF
PD-(L)1 IN THE 7MM
|
11.5
|
INDICATION-WISE MARKET
SIZE OF PD-(L)1 INHIBITORS IN THE 7MM
|
11.6
|
THERAPIES-WISE MARKET
SIZE OF PD-(L)1 INHIBITORS IN THE 7MM
|
11.7
|
THE UNITED STATES
MARKET SIZE
|
11.7.1
|
Indication-wise Market
Size of PD-(L)1 Inhibitors in the United States
|
11.7.2
|
Therapies-wise Market
Size of PD-(L)1 Inhibitors in the United States
|
11.8
|
EU4 AND THE UK MARKET
SIZE
|
11.8.1
|
Indication-wise Market
Size of PD-(L)1 Inhibitors in EU4 and the UK
|
11.8.2
|
Therapies-wise Market
Size of PD-(L)1 Inhibitors in EU4 and the UK
|
11.9
|
JAPAN MARKET
SIZE
|
11.9.1
|
Indication-wise Market
Size of PD-(L)1 Inhibitors in Japan
|
11.9.2
|
Therapies-wise Market
Size of PD-(L)1 Inhibitors in Japan
|
12
|
UNMET NEEDS
|
13
|
SWOT
ANALYSIS
|
14
|
KOL VIEWS
|
15
|
MARKET ACCESS AND
REIMBURSEMENT
|
15.1
|
UNITED
STATES
|
15.2
|
CENTRE FOR MEDICARE
& MEDICAID SERVICES (CMS)
|
15.2.1
|
The Inflation Reduction
Act (IRA)-directed Medicare Price Negotiations
|
15.3
|
UK
|
15.4
|
GERMANY
|
15.5
|
FRANCE
|
16
|
APPENDIX
|
16.1
|
ABBREVIATIONS
|
16.2
|
BIBLIOGRAPHY
|
16.3
|
REPORT
METHODOLOGY
|
17
|
DELVEINSIGHT
CAPABILITIES
|
18
|
DISCLAIMER
|
19
|
ABOUT
DELVEINSIGHT
|
Related Reports
PD-1 and PD-L1 Inhibitors Competitive Landscape
PD-1 and PD-L1 Inhibitors Competitive Landscape –
2024 report provides comprehensive insights about the
pipeline landscape, pipeline drug profiles, including clinical and
non-clinical stage products, and the key PD-1 and PD-L1 inhibitors
companies, including Merck, Laekna Therapeutics, Genentech,
Tracon Pharmaceuticals, Celgene, MedImmune, Hangzhou Sumgen
Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene,
Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics,
Seagen, Ascletis Pharma, Secarna Pharmaceuticals GmbH & Co. KG,
Arbutus Biopharma, among others.
PD-1 Inhibitor Pipeline
PD-1 Inhibitor Pipeline Insight – 2024 report
provides comprehensive insights about the pipeline landscape,
pipeline drug profiles, including clinical and non-clinical stage
products, and the key PD-1 inhibitor companies, including
Genmab, RemeGen, Alphamab, OxSonics therapeutics, Light Chain
Bioscience, ImmuneOnco Biopharma, Alpine Immune Sciences, Shanghai
Henlius Biotech, Ocean Biomedical, Akeso Biopharma, Lyvgen
Biopharma, Prestige Biopharma, ONO Pharmaceutical, among
others.
Immune Checkpoint Inhibitors Competitive Landscape
Immune Checkpoint Inhibitors Competitive Landscape and Market
Forecast – 2032 report provides comprehensive insights
about the pipeline landscape, pipeline drug profiles, including
clinical and non-clinical stage products, and the key immune
checkpoint inhibitors companies, including Regeneron
Pharmaceuticals, GlaxoSmithKline, Roche, Boehringer Ingelheim,
Xencor, Taiga Biotechnologies, Jiangsu Alphamab Biopharmaceuticals,
Dr. Reddy's Laboratories, NATCO Pharma, AstraZeneca, EMD Serono
Research & Development Institute, Bristol-Myers Squibb,
ImmuneSensor Therapeutics, ImmunityBio, SQZ Biotechnologies, Teon
Therapeutics, ALX Oncology, Astellas Pharma, Seagen, Hoffmann-La
Roche, NextCure, MiNK Therapeutics, Genmab, BioNTech SE, STORM
Therapeutics, Suzhou Kintor Pharmaceutical, Sanofi, Coordination
Pharmaceuticals, among others.
Checkpoint Inhibitors Competitive Landscape
Checkpoint Inhibitors Competitive Landscape –
2024 report provides comprehensive insights about the
pipeline landscape, pipeline drug profiles, including clinical and
non-clinical stage products, and the key checkpoint inhibitors
companies, including BeiGene, Apollomics, BCN Biosciences, Phio
Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono,
Innovent Biologics, Agenus, Eucure Biopharma, PharmaEngine,
Vernalis, Array BioPharma, Genentech, Boehringer Ingelheim,
Sentinel Oncology, Sierra Oncology, IMPACT Therapeutics, among
others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo:
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/pd-l1-inhibitors-market-to-remarkable-growth-at-a-cagr-of-5-by-2034-in-the-7mm-delveinsight-302187753.html
SOURCE DelveInsight Business Research, LLP